Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $30

Viridian Therapeutics Inc Ordinary Shares +6.31% Pre

Viridian Therapeutics Inc Ordinary Shares

VRDN

19.89

19.89

+6.31%

0.00% Pre

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ: VRDN) with a Buy and lowers the price target from $40 to $30.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via